SCHEMBL5137919

SCHEMBL5137919

CCCCn1c(CN(CCc2ccccc2)Cc2cc(C)ccc2C)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
HSD11B1 P28845 2/20 0.39
C5AR1 P21730 1/20 0.35
DRD2 P14416 3/20 0.35
OPRM1 P35372 3/20 0.35
DRD3 P35462 3/20 0.35
OPRD1 P41143 3/20 0.35
OPRK1 P41145 3/20 0.35
ALDH1A1 P00352 4/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
USP2 O75604 2/20 0.34
TP53 P04637 2/20 0.34
KCNA5 P22460 1/20 0.34
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
THRB P10828 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136205 0.93 TSHR (0.39) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5137588 0.91 TSHR (0.41) TSHRHSD11B1C5AR1ALDH1A1MAPT
SCHEMBL5135195 0.91 TSHR (0.38) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5137926 0.88 TSHR (0.41) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5134920 0.88 HSD11B1 (0.44) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5075074 0.88 TSHR (0.46) TSHRHSD11B1DRD2OPRM1DRD3
SCHEMBL5135358 0.87 HSD11B1 (0.42) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135727 0.86 TSHR (0.39) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135696 0.85 TSHR (0.40) TSHRHSD11B1
SCHEMBL5135197 0.85 TSHR (0.40) TSHRHSD11B1C5AR1DRD2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed